Peter Thuss-Patience
Berlin oncologist who led GATSBY, the trial showing that the antibody-drug conjugate T-DM1 did not beat taxane chemotherapy in previously treated HER2-positive stomach cancer.
Overview
Peter Thuss-Patience is a gastrointestinal oncologist at Charité in Berlin. He led the German AIO trial that established second-line irinotecan over best supportive care in gastric cancer, and was first author of the 2017 Lancet Oncology report of GATSBY, in which trastuzumab emtansine failed to improve survival over taxane chemotherapy in HER2-positive advanced gastric cancer after first-line treatment.
Similar pages
not linked directly; found by shared links- PersonManish A. Shah
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonHansjochen Wilke
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonSalah-Eddin Al-Batran
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonHitoshi Katai
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonHyung-Ho Kim
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonZev A. Wainberg
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- TrialTherapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.
- PersonMaria De Santis
Shares Charité Universitätsmedizin Berlin and the tag trialist.